Myriad Genetics (MYGN) Equity Ratio (2010 - 2026)

Myriad Genetics (MYGN) has 17 years of Equity Ratio data on file, last reported at 0.5 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.5, down 28.52% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.5 (down 28.52% YoY), and the FY2025 annual result was 0.52, down 23.67% from the prior year.
• Equity Ratio eased to 0.5 in Q1 2026 per MYGN's latest filing, from 0.52 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.78 in Q2 2022 and troughed at 0.5 in Q1 2026.
• A 5-year average of 0.66 and a median of 0.68 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2026: Equity Ratio increased 18.01% in 2022, then slipped 28.52% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.74 in 2022, then dropped by 7.56% to 0.68 in 2023, then dropped by 0.12% to 0.68 in 2024, then dropped by 23.67% to 0.52 in 2025, then slipped by 3.84% to 0.5 in 2026.
• Business Quant data shows MYGN's Equity Ratio at 0.5 in Q1 2026, 0.52 in Q4 2025, and 0.51 in Q3 2025.